Cherenkov-excited luminescence scanned imaging

Zhang, Rongxiao; DSouza, Alisha V.; Gunn, Jason R.; Esipova, Tatiana V.; Vinogradov, Sergei A.; Glaser, Adam K.; Jarvis, Lesley A.; Gladstone, David J.; Pogue, Brian W.

doi:10.1364/ol.40.000827

Cited by 50 publications

(51 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cerenkov imaging has recently gained substantial clinical interest with particularly strong implications in quantifying the effective dose of ionizing radiation deposited during RT. 114, 115 Cerenkov optical emission spanning the UV-Visible spectrum is generated by charged particles in a dielectric medium travelling faster than the phase velocity of light in the same medium and can activate nearby PSs localized at the site of RT treatment. 115, 116 Recently, the proof-of-concept of video rate Cerenkov imaging was presented, providing real time insight to the effective three-dimensional radiation dose deposited during RT, as illustrated in Figure 8.…”

Section: Theranosticsmentioning

confidence: 99%

Photonanomedicine: a convergence of photodynamic therapy and nanotechnology

et al. 2016

View full text Add to dashboard Cite

As clinical nanomedicine has emerged over the past two decades, phototherapeutic advancements using nanotechnology have also evolved and impacted disease management. Because of unique features attributable to the light activation process of molecules, photonanomedicine (PNM) holds significant promise as a personalized, image-guided therapeutic approach for cancer and non-cancer pathologies. The convergence of advanced photochemical therapies such as photodynamic therapy (PDT) and imaging modalities with sophisticated nanotechnologies is enabling the ongoing evolution of fundamental PNM formulations, such as Visudyne®, into progressive forward-looking platforms that integrate theranostics (therapeutics and diagnostics), molecular selectivity, the spatiotemporally controlled release of synergistic therapeutics, along with regulated, sustained drug dosing. Considering that the envisioned goal of these integrated platforms is proving to be realistic, this review will discuss how PNM has evolved over the years as a preclinical and clinical amalgamation of nanotechnology with PDT. The encouraging investigations that emphasize the potent synergy between photochemistry and nanotherapeutics, in addition to the growing realization of the value of these multi-faceted theranostic nanoplatforms, will assist in driving PNM formulations into mainstream oncological clinical practice as a necessary tool in the medical armamentarium.

show abstract

Section: Theranosticsmentioning

confidence: 99%

Photonanomedicine: a convergence of photodynamic therapy and nanotechnology

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Sensing of oxygenation in tissue has been demonstrated [64,68], and sensing of pH with probes is also possible [69]. The examination of idealized probes for sensing depends a bit on the type of radiation used (Beta emitters, vs Gamma, external source vs. internal source, etc).…”

Section: Molecules For čErenkov Sensing and Radiosensitizationmentioning

confidence: 99%

Review of biomedical Čerenkov luminescence imaging applications

Tanha

Pashazadeh

Pogue

2015

Biomed. Opt. Express

View full text Add to dashboard Cite

Čerenkov radiation is a fascinating optical signal, which has been exploited for unique diagnostic biological sensing and imaging, with significantly expanded use just in the last half decade. Čerenkov Luminescence Imaging (CLI) has desirable capabilities for niche applications, using specially designed measurement systems that report on radiation distributions, radiotracer and nanoparticle concentrations, and are directly applied to procedures such as medicine assessment, endoscopy, surgery, quality assurance and dosimetry. When compared to the other imaging tools such as PET and SPECT, CLI can have the key advantage of lower cost, higher throughput and lower imaging time. CLI can also provide imaging and dosimetry information from both radioisotopes and linear accelerator irradiation. The relatively short range of optical photon transport in tissue means that direct Čerenkov luminescence imaging is restricted to small animals or near surface human use. Use of Čerenkov-excitation for additional molecular probes, is now emerging as a key tool for biosensing or radiosensitization. This review evaluates these new improvements in CLI for both medical value and biological insight. References and links 1. P. Čerenkov, "Visible radiation produced by electrons moving in a medium with velocities exceeding the of light," Phys. Rev. 52(4), 378-379 (1937). 2. P. Čerenkov, "Visible Emission of Člean Liquids by Action of $\gamma$ Radiation," Dokl. Akad. Nauk SSSR 2, 451-454 (1934). 3. R. H. Elrick and R. P. Parker, "The use of Cerenkov radiation in the measurement of beta-emitting radionuclides," Int. J. Appl. Radiat. Isot. 19(3), 263-271 (1968). 4. M. K. Johnson, "Counting of Čerenkov radiation from 32P in nonaqueous media," Anal. Biochem. 29(2), 348-350 (1969). 5. F. L. Hoch, R. A. Kuras, and J. D. Jones, "Iodine analysis of biological samples by neutron activation of 127-I, with scintillation counting of Čerenkov radiation," Anal. Biochem. 40(1), 86-94 (1971). 6. G. Bosia, C. Castagnoli, M. Dardo, and G. Marangoni, "Observation of structure in Čerenkov pulses from extensive air showers using fast techniques," Nature 225(5232), 532-533 (1970). 7. W. C. Haxton, "Salty water Čerenkov detectors for solar neutrinos," Phys. Rev. Lett. 76(10), 1562-1565 (1996). Chen, "PET and NIR optical imaging using self-illuminating (64)Cu-doped chelator-free gold nanoclusters," Biomaterials 35(37), 9868-9876 (2014). 72.

show abstract

“…16,18,22 In addition, recent studies have looked at using this Cherenkov emission as an excitation source for molecular imaging applications directly on the medical linear accelerator treatment bed. [23][24][25] Applying Cherenkov imaging to unique treatments such as TSET could ensure more homogeneous dose delivery and provide a new method for TSET protocol commissioning.…”

Section: Introductionmentioning

confidence: 99%

Cherenkov imaging method for rapid optimization of clinical treatment geometry in total skin electron beam therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

Purpose: A method was developed utilizing Cherenkov imaging for rapid and thorough determination of the two gantry angles that produce the most uniform treatment plane during dual-field total skin electron beam therapy (TSET). Methods: Cherenkov imaging was implemented to gather 2D measurements of relative surface dose from 6 MeV electron beams on a white polyethylene sheet. An intensified charge-coupled device camera time-gated to the Linac was used for Cherenkov emission imaging at sixty-two different gantry angles (1 • increments, from 239.5• to 300.5 • ). Following a modified Stanford TSET technique, which uses two fields per patient position for full body coverage, composite images were created as the sum of two beam images on the sheet; each angle pair was evaluated for minimum variation across the patient region of interest. Cherenkov versus dose correlation was verified with ionization chamber measurements. The process was repeated at source to surface distance (SSD) = 441, 370.5, and 300 cm to determine optimal angle spread for varying room geometries. In addition, three patients receiving TSET using a modified Stanford six-dual field technique with 6 MeV electron beams at SSD = 441 cm were imaged during treatment. Results: As in previous studies, Cherenkov intensity was shown to directly correlate with dose for homogenous flat phantoms (R 2 = 0.93), making Cherenkov imaging an appropriate candidate to assess and optimize TSET setup geometry. This method provided dense 2D images allowing 1891 possible treatment geometries to be comprehensively analyzed from one data set of 62 single images. Gantry angles historically used for TSET at their institution were 255.5• and 284.5• at SSD = 441 cm; however, the angles optimized for maximum homogeneity were found to be 252.5• and 287.5• (+6 • increase in angle spread). Ionization chamber measurements confirmed improvement in dose homogeneity across the treatment field from a range of 24.4% at the initial angles, to only 9.8% with the angles optimized. A linear relationship between angle spread and SSD was observed, ranging from 35• at 441 cm, to 39• at 300 cm, with no significant variation in percent-depth dose at midline (R 2 = 0.998). For patient studies, factors influencing in vivo correlation between Cherenkov intensity and measured surface dose are still being investigated. Conclusions: Cherenkov intensity correlates to relative dose measured at depth of maximum dose in a uniform, flat phantom. Imaging of phantoms can thus be used to analyze and optimize TSET treatment geometry more extensively and rapidly than thermoluminescent dosimeters or ionization chambers. This work suggests that there could be an expanded role for Cherenkov imaging as a tool to efficiently improve treatment protocols and as a potential verification tool for routine monitoring of unique patient treatments. C

show abstract

Cherenkov-excited luminescence scanned imaging

Cited by 50 publications

References 14 publications

Photonanomedicine: a convergence of photodynamic therapy and nanotechnology

Photonanomedicine: a convergence of photodynamic therapy and nanotechnology

Review of biomedical Čerenkov luminescence imaging applications

Cherenkov imaging method for rapid optimization of clinical treatment geometry in total skin electron beam therapy

Contact Info

Product

Resources

About